ASN51 + itraconazole

**ASN51 + itraconazole** refers to the investigational co-administration of ASN51, a drug under clinical evaluation, with the approved antifungal agent itraconazole. ASN51 is being studied for drug-drug interactions, particularly how co-administration with potent CYP3A4 inhibitor itraconazole affects its pharmacokinetics. The precise mechanism of action and target of ASN51 is not publicly disclosed. Itraconazole is a triazole antifungal that inhibits lanosterol 14-α-demethylase, an enzyme essential for fungal ergosterol synthesis, thereby compromising fungal cell membrane integrity. The combination is used in drug-drug interaction studies and not as a therapeutic regimen.